- Home
- AR vs DVA Comparison
AR vs DVA Comparison
Compare AR & DVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AR | DVA |
|---|---|---|
| Founded | 2002 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Misc Health and Biotechnology Services |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.9B | 8.4B |
| IPO Year | 2013 | 1995 |
Fundamental Metrics
Financial Performance| Metric | AR | DVA |
|---|---|---|
| Price | $35.24 | $121.51 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 18 | 4 |
| Target Price | $44.35 | ★ $145.00 |
| AVG Volume (30 Days) | ★ 5.7M | 972.4K |
| Earning Date | 10-29-2025 | 10-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 5.63 |
| EPS | 1.87 | ★ 9.76 |
| Revenue | $5,007,754,000.00 | ★ $13,317,965,000.00 |
| Revenue This Year | $22.71 | $6.50 |
| Revenue Next Year | $8.19 | $2.97 |
| P/E Ratio | $18.83 | ★ $12.43 |
| Revenue Growth | ★ 17.21 | 5.14 |
| 52 Week Low | $29.10 | $113.97 |
| 52 Week High | $44.02 | $179.60 |
Technical Indicators
Market Signals| Indicator | AR | DVA |
|---|---|---|
| Relative Strength Index (RSI) | 50.52 | 54.23 |
| Support Level | $36.20 | $115.91 |
| Resistance Level | $38.04 | $122.61 |
| Average True Range (ATR) | 1.22 | 2.30 |
| MACD | -0.05 | 0.54 |
| Stochastic Oscillator | 45.51 | 83.43 |
Price Performance
Historical ComparisonAbout AR Antero Resources Corporation
Antero Resources, based in Denver, explores for and produces natural gas and natural gas liquids in the United States and Canada. At the end of 2024, the company reported proven reserves of 17.9 trillion cubic feet of natural gas equivalent. Production averaged approximately 3,424 million cubic feet of equivalent a day in 2024 at a ratio of 35% liquids and 65% natural gas.
About DVA DaVita Inc.
DaVita is the largest provider of dialysis services in the United States, boasting market share of about 35% when measured by clinics. The firm operates over 3,000 facilities worldwide, mostly in the US, and treats about 280,000 patients globally each year. Government payers dominate US dialysis reimbursement. DaVita receives about two thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business. Berkshire Hathaway owns about 45% of DaVita.